In an oral presentation today,

Pliant Therapeutics· @PliantRX · X·2026-04-19 03:26· 2026-04-19Score60

Body

In an oral presentation today,
@UTMDAnderson
's Dr. Timothy Yap presented updated results from our Phase 1 trial of PLN-101095 in patients with ICI-refractory solid tumors as part of the
@AACR
2026 Annual Meeting. Review the data and presentation
https://
lnkd.in/gCvrb5fQ #AACR26

Heat 0 · 0 likes · 0 replies · 0 reposts

Conference abstracts

CT002NCT06270706matched by 代号 PLN-101095

First-in-human phase I study of PLN-101095, a first-in-class dual αvβ8/αvβ1integrin inhibitor, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors refractory to immune checkpoint inhibitors (ICI)

Timothy A. Yap, Andrae Vandross, Jenny Amaya-Amaya, Chris N. Barnes, Shuguang Ma, Martin Decaris, Keithryn Nicolas, Alexander Spira, Jacqueline Brown, Patricia LoRusso, Manish R. Sharma

Read the abstract →

Source: Pliant Therapeutics · x.com